Athersys to Webcast Presentation at BioAsia Conference

Apr 18, 2001, 01:00 ET from Athersys Inc.

    CLEVELAND, April 18 /PRNewswire/ -- Athersys Inc., a functional genomics
 and biopharmaceutical company, announced today that James J. Kovach, M.D.,
 J.D., executive vice president and chief operating officer is scheduled to
 present at the BioAsia Pacific Conference.
     The presentation is scheduled to take place on Thursday, April 19, 2001 at
 9:00 a.m. HDT (3:00 p.m. ET) from The Sheraton Waikiki in Honolulu, Hawaii.
 During the presentation, Dr. Kovach will provide an overview of Athersys'
 business strategy, recent business development announcements, and the
 Company's RAGE technology. The presentation will be broadcast live via the
 Internet and can be accessed at:
 
      http://www.informedinvestors.com/iif_forums/event.cfm?forumID=176
 
     Following the live presentation, the Webcast will be archived for 30 days.
 
     Athersys Overview
     Athersys is a functional genomics and biopharmaceutical company engaged in
 the development and application of novel research tools and therapeutic
 products. The company's RAGE (Random Activation of Gene Expression)(TM)
 technology platform is a novel gene expression system that enables the company
 to rapidly survey the entire human genome for proteins with a specific
 biological function and to quickly and accurately correlate protein function
 with gene expression. RAGE has powerful applications in functional genomics,
 generation of validated drug targets, development of protein therapeutics, and
 gene discovery. Athersys is establishing a broad portfolio of proprietary
 technologies that positions the company to develop therapeutic products, both
 internally and with strategic partners, to treat significant and
 life-threatening diseases. This press release and further information on
 Athersys, Inc. can be found on the World Wide Web at: http://www.Athersys.com.
 
     Statements herein that are not descriptions of historical facts are
 forward-looking and subject to risk and uncertainties. Actual results could
 differ materially from those currently anticipated due to a number of factors,
 including risks relating to the early stage of products under development;
 uncertainties related to patent protection; uncertainties relating to clinical
 trials; dependence on third parties, including strategic partners,
 collaborators and key personnel; and risks relating to the development and
 commercialization, if any, of Athersys' proposed products (such as
 effectiveness of our products, marketing, manufacturing, safety, regulatory,
 patent or product liability, supply, competition and other risks).
 
 

SOURCE Athersys Inc.
    CLEVELAND, April 18 /PRNewswire/ -- Athersys Inc., a functional genomics
 and biopharmaceutical company, announced today that James J. Kovach, M.D.,
 J.D., executive vice president and chief operating officer is scheduled to
 present at the BioAsia Pacific Conference.
     The presentation is scheduled to take place on Thursday, April 19, 2001 at
 9:00 a.m. HDT (3:00 p.m. ET) from The Sheraton Waikiki in Honolulu, Hawaii.
 During the presentation, Dr. Kovach will provide an overview of Athersys'
 business strategy, recent business development announcements, and the
 Company's RAGE technology. The presentation will be broadcast live via the
 Internet and can be accessed at:
 
      http://www.informedinvestors.com/iif_forums/event.cfm?forumID=176
 
     Following the live presentation, the Webcast will be archived for 30 days.
 
     Athersys Overview
     Athersys is a functional genomics and biopharmaceutical company engaged in
 the development and application of novel research tools and therapeutic
 products. The company's RAGE (Random Activation of Gene Expression)(TM)
 technology platform is a novel gene expression system that enables the company
 to rapidly survey the entire human genome for proteins with a specific
 biological function and to quickly and accurately correlate protein function
 with gene expression. RAGE has powerful applications in functional genomics,
 generation of validated drug targets, development of protein therapeutics, and
 gene discovery. Athersys is establishing a broad portfolio of proprietary
 technologies that positions the company to develop therapeutic products, both
 internally and with strategic partners, to treat significant and
 life-threatening diseases. This press release and further information on
 Athersys, Inc. can be found on the World Wide Web at: http://www.Athersys.com.
 
     Statements herein that are not descriptions of historical facts are
 forward-looking and subject to risk and uncertainties. Actual results could
 differ materially from those currently anticipated due to a number of factors,
 including risks relating to the early stage of products under development;
 uncertainties related to patent protection; uncertainties relating to clinical
 trials; dependence on third parties, including strategic partners,
 collaborators and key personnel; and risks relating to the development and
 commercialization, if any, of Athersys' proposed products (such as
 effectiveness of our products, marketing, manufacturing, safety, regulatory,
 patent or product liability, supply, competition and other risks).
 
 SOURCE  Athersys Inc.